Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

CINPinCB

Financiado

Cerrado

Deciphering tumor promoting mechanisms mediated by neutrophils in vivo

Immunotherapies are revolutionizing cancer care, but are only effective in a minority of patients. Because current treatments typically target T lymphocytes, manipulating other cell types will create additional therapeutic opportu... ver más

30/04/2023

UNIGE

203K€

Presupuesto del proyecto: 203K€

Líder del proyecto

UNIVERSITE DE GENEVE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2023-04-30

MSCA-IF-2020: Individual Fellowships

I+D

Cerrada hace 4 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

UNIGE

203.15K€ | Lider

Proyectos interesantes

TANTUMorNEUVACCINE

Medical Technol...

Data Science

266K€ Cerrado

ProMetNeu

Medical Technol...

Data Science

Cerrado

InflaMet

Medical Technol...

Data Science

2M€ Cerrado

PID2020-113174RA-I00

Medical Technol...

Immunology

209K€ Cerrado

DIEAML

Medical Technol...

Data Science

163K€ Cerrado

SAF2015-66365-R

Medical Technol...

Cancer Research

133K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 25 meses Fecha Inicio: 2021-03-19
Fecha Fin: 2023-04-30

Líder del proyecto

UNIVERSITE DE GENEVE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 203K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Immunotherapies are revolutionizing cancer care, but are only effective in a minority of patients. Because current treatments typically target T lymphocytes, manipulating other cell types will create additional therapeutic opportunities. This research project aims to study neutrophils, because they can be abundant in the tumor environment, can modulate tumor outgrowth and response to treatments, and are candidate new therapeutic targets. However, tumor-associated neutrophils can be phenotypically and functionally heterogeneous, with only some of them promoting tumor growth. At present, we have a limited understanding of the complexity of neutrophils in tumors, and the mechanisms that control the functions of these cells. This is largely due to the inherent experimental limitations of neutrophil studies. Here, we will use a new approach to test the hypotheses that so-called Conditionally-Immortalized Neutrophil Progenitors (CINP) can be: 1) used to produce unrestricted numbers of tumor-associated neutrophils in vivo, and 2) gene-edited to study neutrophils mechanistically during cancer progression. Addressing these questions bears scientific and therapeutic importance, as it will not only deepen our fundamental understanding of the mechanisms regulating neutrophil activities in cancer, but also indicate new molecular targets for therapy. With this study, I will also create and share a publicly available database of all newly identified targets that will be investigated by us, other academic research groups, and industry. Besides, the project’s outputs will be communicated to the broader general public. Altogether, the training and input I will receive during the Marie Curie Individual Fellowship will prepare my transition from post-doc to independent researcher in an excellent scientific environment in Europe.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores